Abstract: The present disclosure provides a pharmaceutical composition comprising a NUPR1 isoform A inhibitor as an active ingredient. Pharmaceutical compositions comprising an NUPR1 isoform A inhibitor may be used in methods of preventing or treating cancer, in methods of diagnosing or predicting prognosis of cancer comprising an agent for measuring an expression or activity level of a NUPR1 isoform A, in a kit for diagnosing or predicting prognosis of cancer comprising the composition, methods for screening a substance for inhibiting cancer cell proliferation or metastasis, methods for providing information for cancer cell proliferation or metastasis, in food compositions for preventing or improving cancer comprising a NUPR1 isoform A inhibitor as an active ingredient, and in feed compositions for preventing or improving cancer comprising a NUPR1 isoform A inhibitor as an active ingredient.

Abstract: A magnetic resonance imaging (MRI)-based alternating magnetic field (AMF) treatment system according to one embodiment of the technical idea of the present invention comprises an MRI device including an MRI coil system, and is configured to generate an AMF by applying an alternating current to the MRI coil system in the MRI device.